21:38 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg IV ARB-1467 every...
19:32 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Xeltis raises EUR45M series C

Xeltis AG (Zurich, Switzerland) said it raised €45 million ($52.5 million) on Nov. 15 in an oversubscribed series C financing led by an undisclosed global strategic investor, with participation from Ysios Capital and existing investors...
07:00 , Oct 13, 2016 |  BC Innovations  |  Product R&D

Elastic bones

A group at Northwestern University has created a "hyperelastic bone" scaffold to address the need for a bone-inducing material that is easily manufactured, low cost and easy to manipulate during surgery. While the short-term goal...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

Cytori, U.S. Department of Health and Human Services gene/cell therapy, other news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) amended for a second time an option it exercised in August 2014 under Cytori’s September 2012 contract to develop a cell therapy to treat thermal burns from...
07:00 , Sep 12, 2016 |  BioCentury  |  Regulation

Adding to A1c

Diabetes patients and researchers are zeroing in on a collection of endpoints they say would be more useful than HbA1c for choosing among treatment options. The standard endpoint is useful in predicting serious microvascular complications...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Avita sales and marketing update

Avita launched ReGenerCell and ReNovaCell in Europe. Both autologous cell harvesting devices have CE Mark approval. ReGenerCell is approved to treat chronic wounds, such as venous leg ulcers and diabetic foot ulcers. ReNovaCell is approved...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

ReCell dermatology data

Data from 8 adults and 4 pediatric patients with large, thermal burns who were treated with ReCell as an adjunct to grafting under a compassionate use investigational device exemption (IDE) showed that the length of...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Avita sales and marketing update

FDA approved expansion of an investigational device exemption (IDE) for ReCell Spray-on-Skin from Avita to increase the number of patients permitted under the IDE to 24 from 12.The IDE covers patients with insufficient healthy skin...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

Cytori, U.S. Department of Health and Human Services gene/cell therapy, other news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) amended an option it exercised last August under the company’s September 2012 contract to develop a cell therapy to treat thermal burns from radiation injury. The amendment...
03:14 , Dec 20, 2014 |  BC Extra  |  Company News

FDA strikes twice for Cerus

Three days after FDA approved the Intercept Blood System for plasma , Cerus Corp. (NASDAQ:CERS) announced the agency approved the company's Intercept system for platelets. Cerus shares rose $0.25 to $6.41 on Friday; they have...